Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis

Status Completed

Clinical Trial Summary

The purpose of conducting phase 1 trial to evaluate the safety and tolerability of allogenic bone marrow-derived mesenchymal stem cells(CS20AT04) in subjects with lupus nephritis.

Evaluating DLT by IV injection according to dose-escalating in lupus nephritis patients.

Clinical Trial Description

Lupus is a representative autoimmune disease that affects the whole body. It is occurred by generation of autoantibody and immune complex due to abnormal activation of the immune cells on the basis of abnormal immune responses.

Although about 50% of lupus patients have lupus nephritis, there is no therapy product targeted for the lupus nephritis now.

We have performed the pre-clinical and clinical studies using allogenic bone marrow derived mesenchymal stem cells in SLE.

CS20AT04 has anti-inflammatory effects, controls activity of immune cells and reduces generation of autoantibodies. So, it is expected to have treatment effects of lupus nephritis.

The clinical trial was designed as a single center, open-label, phase 1 clinical trials.

If that subject's written informed consent form to participate in this clinical trial will be conducted the required examinations and tests in accordance with the study protocol within 56 days investigational drug administration.

Then, the register for each dose step. For the final 3 subjects in the inclusion / exclusion criteria and be administered a drug test.

Check the adverse events for more than four hours after administration of the investigational drug, and will determine whether the expression of adverse drug reaction(ADR) by the visit after 3 days, 7 days and 28 days.

Except for dose administration, all subject are tested in the same schedule. As a result of evaluating severity of AE divided into grades in accordance with the CTCAE (Version 4.0) standards. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03174587
Study type	Interventional
Source	Corestem, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	May 30, 2017
Completion date	August 19, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02936375` - The Iguratimod Effect on Lupus Nephritis (IGeLU)	Phase 2
Completed	`NCT03597464` - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin	Phase 3
Recruiting	`NCT01226147` - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis	Phase 2
Completed	`NCT01206569` - Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis	Phase 4
Active, not recruiting	`NCT00569101` - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis	Phase 2
Terminated	`NCT00368264` - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )	Phase 2/Phase 3
Completed	`NCT00298506` - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)	N/A
Completed	`NCT00371319` - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis	Phase 4
Completed	`NCT00094380` - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)	Phase 1/Phase 2
Terminated	`NCT04376827` - A Study of Guselkumab in Participants With Active Lupus Nephritis	Phase 2
Completed	`NCT03610516` - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.	Phase 2
Recruiting	`NCT03526042` - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis	N/A
Withdrawn	`NCT03859570` - Pentoxifylline in Lupus Nephritis	Phase 4
Completed	`NCT03664908` - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?	N/A
Completed	`NCT01085097` - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis	Phase 2
Active, not recruiting	`NCT05704088` - SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients	Phase 4
Not yet recruiting	`NCT06429800` - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis	Phase 1
Recruiting	`NCT02226341` - ACTHar in the Treatment of Lupus Nephritis	Phase 4
Recruiting	`NCT02453997` - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis	N/A
Completed	`NCT01470183` - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients	N/A